Literature DB >> 28629675

Misdiagnosis is an important factor for diagnostic delay in McArdle disease.

Renata Siciliani Scalco1, Jasper M Morrow2, Suzanne Booth2, Sherryl Chatfield2, Richard Godfrey3, Ros Quinlivan4.   

Abstract

Diagnosis of McArdle disease is frequently delayed by many years following the first presentation of symptoms to a health professional. The aim of this study was to investigate the importance of misdiagnosis in delaying diagnosis of McArdle disease. The frequency of misdiagnosis, duration of diagnostic delay, categories of misdiagnoses and inappropriate medical interventions were assessed in 50 genetically confirmed patients. The results demonstrated a high frequency of misdiagnosis (90%, n = 45/50) most commonly during childhood years (67%; n = 30/45) compared with teenage years and adulthood (teenage: n = 7/45; adult n = 5/45; not known n = 3/45). The correct diagnosis of McArdle disease was rarely made before adulthood (median age of diagnosis 33 years). Thirty-one patients (62%) reported having received more than one misdiagnosis; the most common were "growing pains" (40%, n = 20) and "laziness/being unfit" (46%, n = 23). A psychiatric/psychological misdiagnosis was significantly more common in females than males (females 6/20; males 1/30; p < 0.01). Of the 45 patients who were misdiagnosed, 21 (47%) received incorrect management. This study shows that most patients with McArdle disease received an incorrect explanation of their symptoms providing evidence that misdiagnosis plays an important part in delaying implementation of appropriate medical advice and management to this group of patients.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Exercise intolerance; Glycogen storage disease type V; Growing pains; McArdle disease; Myoglobinuria; Rhabdomyolysis

Mesh:

Year:  2017        PMID: 28629675     DOI: 10.1016/j.nmd.2017.04.013

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  4 in total

1.  Non-osteogenic muscle hypertrophy in children with McArdle disease.

Authors:  I Rodríguez-Gómez; A Santalla; J Díez-Bermejo; D Munguía-Izquierdo; L M Alegre; G Nogales-Gadea; J Arenas; M A Martín; A Lucía; I Ara
Journal:  J Inherit Metab Dis       Date:  2018-03-28       Impact factor: 4.982

2.  Diagnostic delay in patients with FKRP-related muscular dystrophy.

Authors:  Lauren N Coffey; Carrie M Stephan; M B Zimmerman; Chyan K Decker; Katherine D Mathews
Journal:  Neuromuscul Disord       Date:  2021-09-06       Impact factor: 4.296

Review 3.  Genetic Modifiers and Rare Mendelian Disease.

Authors:  K M Tahsin Hassan Rahit; Maja Tarailo-Graovac
Journal:  Genes (Basel)       Date:  2020-02-25       Impact factor: 4.096

4.  Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC).

Authors:  Renata S Scalco; Alejandro Lucia; Alfredo Santalla; Andrea Martinuzzi; Marinela Vavla; Gianluigi Reni; Antonio Toscano; Olimpia Musumeci; Nicol C Voermans; Carlyn V Kouwenberg; Pascal Laforêt; Beatriz San-Millán; Irene Vieitez; Gabriele Siciliano; Enrico Kühnle; Rebeca Trost; Sabrina Sacconi; Mads G Stemmerik; Hacer Durmus; Biruta Kierdaszuk; Andrew Wakelin; Antoni L Andreu; Tomàs Pinós; Ramon Marti; Ros Quinlivan; John Vissing
Journal:  Orphanet J Rare Dis       Date:  2020-11-24       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.